Compile Data Set for Download or QSAR
Report error Found 272 Enz. Inhib. hit(s) with all data for entry = 694
TargetCytochrome P450 11B2, mitochondrial(Human)
Viamet Pharmaceuticals (Bermuda)

US Patent
LigandPNGBDBM287691(US10085984, Example 69 | US11040034, Ex. No. 69)
Affinity DataIC50: 100nMAssay Description:V79-4 cells expressing recombinant andrenodoxin and andrenodoxin reductase with either recombinant human CYP11B2 or CYP11B1 were prepared according t...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/17/2019
Entry Details
US Patent

TargetCytochrome P450 11B2, mitochondrial(Human)
Viamet Pharmaceuticals (Bermuda)

US Patent
LigandPNGBDBM287628(US10085984, Example 6 | US11040034, Ex. No. 6)
Affinity DataIC50: 100nMAssay Description:V79-4 cells expressing recombinant andrenodoxin and andrenodoxin reductase with either recombinant human CYP11B2 or CYP11B1 were prepared according t...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/17/2019
Entry Details
US Patent

TargetCytochrome P450 11B2, mitochondrial(Human)
Viamet Pharmaceuticals (Bermuda)

US Patent
LigandPNGBDBM287692(US10085984, Example 70 | US11040034, Ex. No. 70)
Affinity DataIC50: 100nMAssay Description:V79-4 cells expressing recombinant andrenodoxin and andrenodoxin reductase with either recombinant human CYP11B2 or CYP11B1 were prepared according t...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/17/2019
Entry Details
US Patent

TargetCytochrome P450 11B2, mitochondrial(Human)
Viamet Pharmaceuticals (Bermuda)

US Patent
LigandPNGBDBM287629(US10085984, Example 7 | US11040034, Ex. No. 7)
Affinity DataIC50: 100nMAssay Description:V79-4 cells expressing recombinant andrenodoxin and andrenodoxin reductase with either recombinant human CYP11B2 or CYP11B1 were prepared according t...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/17/2019
Entry Details
US Patent

TargetCytochrome P450 11B2, mitochondrial(Human)
Viamet Pharmaceuticals (Bermuda)

US Patent
LigandPNGBDBM287693(US10085984, Example 71 | US11040034, Ex. No. 71)
Affinity DataIC50: 100nMAssay Description:V79-4 cells expressing recombinant andrenodoxin and andrenodoxin reductase with either recombinant human CYP11B2 or CYP11B1 were prepared according t...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/17/2019
Entry Details
US Patent

TargetCytochrome P450 11B2, mitochondrial(Human)
Viamet Pharmaceuticals (Bermuda)

US Patent
LigandPNGBDBM287758(US10085984, Example 136 | US11040034, Ex. No. 136)
Affinity DataIC50: 100nMAssay Description:V79-4 cells expressing recombinant andrenodoxin and andrenodoxin reductase with either recombinant human CYP11B2 or CYP11B1 were prepared according t...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/17/2019
Entry Details
US Patent

TargetCytochrome P450 11B2, mitochondrial(Human)
Viamet Pharmaceuticals (Bermuda)

US Patent
LigandPNGBDBM287694(US10085984, Example 72 | US11040034, Ex. No. 72)
Affinity DataIC50: 100nMAssay Description:V79-4 cells expressing recombinant andrenodoxin and andrenodoxin reductase with either recombinant human CYP11B2 or CYP11B1 were prepared according t...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/17/2019
Entry Details
US Patent

TargetCytochrome P450 11B2, mitochondrial(Human)
Viamet Pharmaceuticals (Bermuda)

US Patent
LigandPNGBDBM287751(US10085984, Example 129 | US11040034, Ex. No. 129)
Affinity DataIC50: 100nMAssay Description:V79-4 cells expressing recombinant andrenodoxin and andrenodoxin reductase with either recombinant human CYP11B2 or CYP11B1 were prepared according t...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/17/2019
Entry Details
US Patent

TargetCytochrome P450 11B2, mitochondrial(Human)
Viamet Pharmaceuticals (Bermuda)

US Patent
LigandPNGBDBM287688(US10085984, Example 66 | US11040034, Ex. No. 66)
Affinity DataIC50: 100nMAssay Description:V79-4 cells expressing recombinant andrenodoxin and andrenodoxin reductase with either recombinant human CYP11B2 or CYP11B1 were prepared according t...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/17/2019
Entry Details
US Patent

TargetCytochrome P450 11B2, mitochondrial(Human)
Viamet Pharmaceuticals (Bermuda)

US Patent
LigandPNGBDBM287689(US10085984, Example 67 | US11040034, Ex. No. 67)
Affinity DataIC50: 100nMAssay Description:V79-4 cells expressing recombinant andrenodoxin and andrenodoxin reductase with either recombinant human CYP11B2 or CYP11B1 were prepared according t...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/17/2019
Entry Details
US Patent

TargetCytochrome P450 11B2, mitochondrial(Human)
Viamet Pharmaceuticals (Bermuda)

US Patent
LigandPNGBDBM287626(US10085984, Example 4 | US11040034, Ex. No. 4)
Affinity DataIC50: 100nMAssay Description:V79-4 cells expressing recombinant andrenodoxin and andrenodoxin reductase with either recombinant human CYP11B2 or CYP11B1 were prepared according t...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/17/2019
Entry Details
US Patent

TargetCytochrome P450 11B2, mitochondrial(Human)
Viamet Pharmaceuticals (Bermuda)

US Patent
LigandPNGBDBM287636(US10085984, Example 14 | US11040034, Ex. No. 14)
Affinity DataIC50: 100nMAssay Description:V79-4 cells expressing recombinant andrenodoxin and andrenodoxin reductase with either recombinant human CYP11B2 or CYP11B1 were prepared according t...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/17/2019
Entry Details
US Patent

TargetCytochrome P450 11B2, mitochondrial(Human)
Viamet Pharmaceuticals (Bermuda)

US Patent
LigandPNGBDBM287637(US10085984, Example 15 | US11040034, Ex. No. 15)
Affinity DataIC50: 100nMAssay Description:V79-4 cells expressing recombinant andrenodoxin and andrenodoxin reductase with either recombinant human CYP11B2 or CYP11B1 were prepared according t...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/17/2019
Entry Details
US Patent

TargetCytochrome P450 11B2, mitochondrial(Human)
Viamet Pharmaceuticals (Bermuda)

US Patent
LigandPNGBDBM287632(US10085984, Example 10 | US11040034, Ex. No. 10)
Affinity DataIC50: 100nMAssay Description:V79-4 cells expressing recombinant andrenodoxin and andrenodoxin reductase with either recombinant human CYP11B2 or CYP11B1 were prepared according t...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/17/2019
Entry Details
US Patent

TargetCytochrome P450 11B2, mitochondrial(Human)
Viamet Pharmaceuticals (Bermuda)

US Patent
LigandPNGBDBM287696(US10085984, Example 74 | US11040034, Ex. No. 74)
Affinity DataIC50: 100nMAssay Description:V79-4 cells expressing recombinant andrenodoxin and andrenodoxin reductase with either recombinant human CYP11B2 or CYP11B1 were prepared according t...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/17/2019
Entry Details
US Patent

TargetCytochrome P450 11B2, mitochondrial(Human)
Viamet Pharmaceuticals (Bermuda)

US Patent
LigandPNGBDBM287633(US10085984, Example 11 | US11040034, Ex. No. 11)
Affinity DataIC50: 100nMAssay Description:V79-4 cells expressing recombinant andrenodoxin and andrenodoxin reductase with either recombinant human CYP11B2 or CYP11B1 were prepared according t...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/17/2019
Entry Details
US Patent

TargetCytochrome P450 11B2, mitochondrial(Human)
Viamet Pharmaceuticals (Bermuda)

US Patent
LigandPNGBDBM287697(US10085984, Example 75 | US11040034, Ex. No. 75)
Affinity DataIC50: 100nMAssay Description:V79-4 cells expressing recombinant andrenodoxin and andrenodoxin reductase with either recombinant human CYP11B2 or CYP11B1 were prepared according t...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/17/2019
Entry Details
US Patent

TargetCytochrome P450 11B2, mitochondrial(Human)
Viamet Pharmaceuticals (Bermuda)

US Patent
LigandPNGBDBM287634(US10085984, Example 12 | US11040034, Ex. No. 12)
Affinity DataIC50: 100nMAssay Description:V79-4 cells expressing recombinant andrenodoxin and andrenodoxin reductase with either recombinant human CYP11B2 or CYP11B1 were prepared according t...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/17/2019
Entry Details
US Patent

TargetCytochrome P450 11B2, mitochondrial(Human)
Viamet Pharmaceuticals (Bermuda)

US Patent
LigandPNGBDBM287698(US10085984, Example 76 | US11040034, Ex. No. 76)
Affinity DataIC50: 100nMAssay Description:V79-4 cells expressing recombinant andrenodoxin and andrenodoxin reductase with either recombinant human CYP11B2 or CYP11B1 were prepared according t...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/17/2019
Entry Details
US Patent

TargetCytochrome P450 11B2, mitochondrial(Human)
Viamet Pharmaceuticals (Bermuda)

US Patent
LigandPNGBDBM287643(US10085984, Example 21 | US11040034, Ex. No. 21)
Affinity DataIC50: 100nMAssay Description:V79-4 cells expressing recombinant andrenodoxin and andrenodoxin reductase with either recombinant human CYP11B2 or CYP11B1 were prepared according t...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/17/2019
Entry Details
US Patent

TargetCytochrome P450 11B2, mitochondrial(Human)
Viamet Pharmaceuticals (Bermuda)

US Patent
LigandPNGBDBM287707(US10085984, Example 85 | US11040034, Ex. No. 85)
Affinity DataIC50: 100nMAssay Description:V79-4 cells expressing recombinant andrenodoxin and andrenodoxin reductase with either recombinant human CYP11B2 or CYP11B1 were prepared according t...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/17/2019
Entry Details
US Patent

TargetCytochrome P450 11B2, mitochondrial(Human)
Viamet Pharmaceuticals (Bermuda)

US Patent
LigandPNGBDBM287644(US10085984, Example 22 | US11040034, Ex. No. 22)
Affinity DataIC50: 100nMAssay Description:V79-4 cells expressing recombinant andrenodoxin and andrenodoxin reductase with either recombinant human CYP11B2 or CYP11B1 were prepared according t...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/17/2019
Entry Details
US Patent

TargetCytochrome P450 11B2, mitochondrial(Human)
Viamet Pharmaceuticals (Bermuda)

US Patent
LigandPNGBDBM287708(US10085984, Example 86 | US11040034, Ex. No. 86)
Affinity DataIC50: 100nMAssay Description:V79-4 cells expressing recombinant andrenodoxin and andrenodoxin reductase with either recombinant human CYP11B2 or CYP11B1 were prepared according t...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/17/2019
Entry Details
US Patent

TargetCytochrome P450 11B2, mitochondrial(Human)
Viamet Pharmaceuticals (Bermuda)

US Patent
LigandPNGBDBM287645(US10085984, Example 23 | US11040034, Ex. No. 23)
Affinity DataIC50: 100nMAssay Description:V79-4 cells expressing recombinant andrenodoxin and andrenodoxin reductase with either recombinant human CYP11B2 or CYP11B1 were prepared according t...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/17/2019
Entry Details
US Patent

TargetCytochrome P450 11B2, mitochondrial(Human)
Viamet Pharmaceuticals (Bermuda)

US Patent
LigandPNGBDBM287709(US10085984, Example 87 | US11040034, Ex. No. 87)
Affinity DataIC50: 100nMAssay Description:V79-4 cells expressing recombinant andrenodoxin and andrenodoxin reductase with either recombinant human CYP11B2 or CYP11B1 were prepared according t...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/17/2019
Entry Details
US Patent

TargetCytochrome P450 11B1, mitochondrial(Human)
Viamet Pharmaceuticals (Bermuda)

US Patent
LigandPNGBDBM287709(US10085984, Example 87 | US11040034, Ex. No. 87)
Affinity DataIC50: 100nMAssay Description:V79-4 cells expressing recombinant andrenodoxin and andrenodoxin reductase with either recombinant human CYP11B2 or CYP11B1 were prepared according t...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/17/2019
Entry Details
US Patent

TargetCytochrome P450 11B2, mitochondrial(Human)
Viamet Pharmaceuticals (Bermuda)

US Patent
LigandPNGBDBM287646(US10085984, Example 24 | US11040034, Ex. No. 24)
Affinity DataIC50: 100nMAssay Description:V79-4 cells expressing recombinant andrenodoxin and andrenodoxin reductase with either recombinant human CYP11B2 or CYP11B1 were prepared according t...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/17/2019
Entry Details
US Patent

TargetCytochrome P450 11B2, mitochondrial(Human)
Viamet Pharmaceuticals (Bermuda)

US Patent
LigandPNGBDBM287710(US10085984, Example 88 | US11040034, Ex. No. 88)
Affinity DataIC50: 100nMAssay Description:V79-4 cells expressing recombinant andrenodoxin and andrenodoxin reductase with either recombinant human CYP11B2 or CYP11B1 were prepared according t...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/17/2019
Entry Details
US Patent

TargetCytochrome P450 11B2, mitochondrial(Human)
Viamet Pharmaceuticals (Bermuda)

US Patent
LigandPNGBDBM287703(US10085984, Example 81 | US11040034, Ex. No. 81)
Affinity DataIC50: 100nMAssay Description:V79-4 cells expressing recombinant andrenodoxin and andrenodoxin reductase with either recombinant human CYP11B2 or CYP11B1 were prepared according t...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/17/2019
Entry Details
US Patent

TargetCytochrome P450 11B2, mitochondrial(Human)
Viamet Pharmaceuticals (Bermuda)

US Patent
LigandPNGBDBM287640(US10085984, Example 18 | US11040034, Ex. No. 18)
Affinity DataIC50: 100nMAssay Description:V79-4 cells expressing recombinant andrenodoxin and andrenodoxin reductase with either recombinant human CYP11B2 or CYP11B1 were prepared according t...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/17/2019
Entry Details
US Patent

TargetCytochrome P450 11B2, mitochondrial(Human)
Viamet Pharmaceuticals (Bermuda)

US Patent
LigandPNGBDBM287641(US10085984, Example 19 | US11040034, Ex. No. 19)
Affinity DataIC50: 100nMAssay Description:V79-4 cells expressing recombinant andrenodoxin and andrenodoxin reductase with either recombinant human CYP11B2 or CYP11B1 were prepared according t...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/17/2019
Entry Details
US Patent

TargetCytochrome P450 11B2, mitochondrial(Human)
Viamet Pharmaceuticals (Bermuda)

US Patent
LigandPNGBDBM287705(US10085984, Example 83 | US11040034, Ex. No. 83)
Affinity DataIC50: 100nMAssay Description:V79-4 cells expressing recombinant andrenodoxin and andrenodoxin reductase with either recombinant human CYP11B2 or CYP11B1 were prepared according t...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/17/2019
Entry Details
US Patent

TargetCytochrome P450 11B2, mitochondrial(Human)
Viamet Pharmaceuticals (Bermuda)

US Patent
LigandPNGBDBM287706(US10085984, Example 84)
Affinity DataIC50: 100nMAssay Description:V79-4 cells expressing recombinant andrenodoxin and andrenodoxin reductase with either recombinant human CYP11B2 or CYP11B1 were prepared according t...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/17/2019
Entry Details
US Patent

TargetCytochrome P450 11B2, mitochondrial(Human)
Viamet Pharmaceuticals (Bermuda)

US Patent
LigandPNGBDBM287651(US10085984, Example 29 | US11040034, Ex. No. 29)
Affinity DataIC50: 100nMAssay Description:V79-4 cells expressing recombinant andrenodoxin and andrenodoxin reductase with either recombinant human CYP11B2 or CYP11B1 were prepared according t...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/17/2019
Entry Details
US Patent

TargetCytochrome P450 11B2, mitochondrial(Human)
Viamet Pharmaceuticals (Bermuda)

US Patent
LigandPNGBDBM287715(US10085984, Example 93 | US11040034, Ex. No. 93)
Affinity DataIC50: 100nMAssay Description:V79-4 cells expressing recombinant andrenodoxin and andrenodoxin reductase with either recombinant human CYP11B2 or CYP11B1 were prepared according t...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/17/2019
Entry Details
US Patent

TargetCytochrome P450 11B2, mitochondrial(Human)
Viamet Pharmaceuticals (Bermuda)

US Patent
LigandPNGBDBM287652(US10085984, Example 30 | US11040034, Ex. No. 30)
Affinity DataIC50: 100nMAssay Description:V79-4 cells expressing recombinant andrenodoxin and andrenodoxin reductase with either recombinant human CYP11B2 or CYP11B1 were prepared according t...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/17/2019
Entry Details
US Patent

TargetCytochrome P450 11B2, mitochondrial(Human)
Viamet Pharmaceuticals (Bermuda)

US Patent
LigandPNGBDBM287653(US10085984, Example 31 | US11040034, Ex. No. 31)
Affinity DataIC50: 100nMAssay Description:V79-4 cells expressing recombinant andrenodoxin and andrenodoxin reductase with either recombinant human CYP11B2 or CYP11B1 were prepared according t...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/17/2019
Entry Details
US Patent

TargetCytochrome P450 11B2, mitochondrial(Human)
Viamet Pharmaceuticals (Bermuda)

US Patent
LigandPNGBDBM287717(US10085984, Example 95 | US11040034, Ex. No. 95)
Affinity DataIC50: 100nMAssay Description:V79-4 cells expressing recombinant andrenodoxin and andrenodoxin reductase with either recombinant human CYP11B2 or CYP11B1 were prepared according t...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/17/2019
Entry Details
US Patent

TargetCytochrome P450 11B2, mitochondrial(Human)
Viamet Pharmaceuticals (Bermuda)

US Patent
LigandPNGBDBM287654(US10085984, Example 32 | US11040034, Ex. No. 32)
Affinity DataIC50: 100nMAssay Description:V79-4 cells expressing recombinant andrenodoxin and andrenodoxin reductase with either recombinant human CYP11B2 or CYP11B1 were prepared according t...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/17/2019
Entry Details
US Patent

TargetCytochrome P450 11B2, mitochondrial(Human)
Viamet Pharmaceuticals (Bermuda)

US Patent
LigandPNGBDBM287647(US10085984, Example 25 | US11040034, Ex. No. 25)
Affinity DataIC50: 100nMAssay Description:V79-4 cells expressing recombinant andrenodoxin and andrenodoxin reductase with either recombinant human CYP11B2 or CYP11B1 were prepared according t...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/17/2019
Entry Details
US Patent

TargetCytochrome P450 11B2, mitochondrial(Human)
Viamet Pharmaceuticals (Bermuda)

US Patent
LigandPNGBDBM287711(US10085984, Example 89 | US11040034, Ex. No. 89)
Affinity DataIC50: 100nMAssay Description:V79-4 cells expressing recombinant andrenodoxin and andrenodoxin reductase with either recombinant human CYP11B2 or CYP11B1 were prepared according t...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/17/2019
Entry Details
US Patent

TargetCytochrome P450 11B2, mitochondrial(Human)
Viamet Pharmaceuticals (Bermuda)

US Patent
LigandPNGBDBM287648(US10085984, Example 26 | US11040034, Ex. No. 26)
Affinity DataIC50: 100nMAssay Description:V79-4 cells expressing recombinant andrenodoxin and andrenodoxin reductase with either recombinant human CYP11B2 or CYP11B1 were prepared according t...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/17/2019
Entry Details
US Patent

TargetCytochrome P450 11B2, mitochondrial(Human)
Viamet Pharmaceuticals (Bermuda)

US Patent
LigandPNGBDBM287649(US10085984, Example 27 | US11040034, Ex. No. 27)
Affinity DataIC50: 100nMAssay Description:V79-4 cells expressing recombinant andrenodoxin and andrenodoxin reductase with either recombinant human CYP11B2 or CYP11B1 were prepared according t...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/17/2019
Entry Details
US Patent

TargetCytochrome P450 11B2, mitochondrial(Human)
Viamet Pharmaceuticals (Bermuda)

US Patent
LigandPNGBDBM287713(US10085984, Example 91 | US11040034, Ex. No. 91)
Affinity DataIC50: 100nMAssay Description:V79-4 cells expressing recombinant andrenodoxin and andrenodoxin reductase with either recombinant human CYP11B2 or CYP11B1 were prepared according t...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/17/2019
Entry Details
US Patent

TargetCytochrome P450 11B2, mitochondrial(Human)
Viamet Pharmaceuticals (Bermuda)

US Patent
LigandPNGBDBM287650(US10085984, Example 28 | US11040034, Ex. No. 28)
Affinity DataIC50: 100nMAssay Description:V79-4 cells expressing recombinant andrenodoxin and andrenodoxin reductase with either recombinant human CYP11B2 or CYP11B1 were prepared according t...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/17/2019
Entry Details
US Patent

TargetCytochrome P450 11B2, mitochondrial(Human)
Viamet Pharmaceuticals (Bermuda)

US Patent
LigandPNGBDBM287714(US10085984, Example 92 | US11040034, Ex. No. 92)
Affinity DataIC50: 100nMAssay Description:V79-4 cells expressing recombinant andrenodoxin and andrenodoxin reductase with either recombinant human CYP11B2 or CYP11B1 were prepared according t...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/17/2019
Entry Details
US Patent

TargetCytochrome P450 11B2, mitochondrial(Human)
Viamet Pharmaceuticals (Bermuda)

US Patent
LigandPNGBDBM287659(US10085984, Example 37 | US11040034, Ex. No. 37)
Affinity DataIC50: 100nMAssay Description:V79-4 cells expressing recombinant andrenodoxin and andrenodoxin reductase with either recombinant human CYP11B2 or CYP11B1 were prepared according t...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/17/2019
Entry Details
US Patent

TargetCytochrome P450 11B2, mitochondrial(Human)
Viamet Pharmaceuticals (Bermuda)

US Patent
LigandPNGBDBM287723(US10085984, Example 101 | US11040034, Ex. No. 101)
Affinity DataIC50: 100nMAssay Description:V79-4 cells expressing recombinant andrenodoxin and andrenodoxin reductase with either recombinant human CYP11B2 or CYP11B1 were prepared according t...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/17/2019
Entry Details
US Patent

TargetCytochrome P450 11B2, mitochondrial(Human)
Viamet Pharmaceuticals (Bermuda)

US Patent
LigandPNGBDBM287660(US10085984, Example 38 | US11040034, Ex. No. 38)
Affinity DataIC50: 100nMAssay Description:V79-4 cells expressing recombinant andrenodoxin and andrenodoxin reductase with either recombinant human CYP11B2 or CYP11B1 were prepared according t...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/17/2019
Entry Details
US Patent

TargetCytochrome P450 11B2, mitochondrial(Human)
Viamet Pharmaceuticals (Bermuda)

US Patent
LigandPNGBDBM287724(US10085984, Example 102 | US11040034, Ex. No. 102)
Affinity DataIC50: 100nMAssay Description:V79-4 cells expressing recombinant andrenodoxin and andrenodoxin reductase with either recombinant human CYP11B2 or CYP11B1 were prepared according t...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/17/2019
Entry Details
US Patent

Displayed 1 to 50 (of 272 total ) | Next | Last >>
Jump to: